Gynecologic Oncology

If proven effective, the vaccine, called VGX-3100, would be the first non-ablative therapy for cervical precancer.

A look at whether or not oral contraceptives help with ovarian cancer survival. Plus: Do false-positive mammogram results serve as a sign of future breast cancer risk?

It rarely signifies uterine cancer, according to this study.

Change in Pap smear recommendation has meant fewer occasions for testing for the STI, according to one study.

Results of a multi center observational study suggest that testing for a panel of genes may be the wave of the future for hereditary breast and ovarian cancer and alter the course of clinical management.

What are the current recommendations for managing women who are BRCA 1 or 2 carriers?

A new study looks at whether or not women with dense breasts require alternative screening methods. Conventional wisdom about reducing salt intake to lower blood pressure may not be correct. What's the impact of breastfeeding on reducing the recurrence of certain breast cancer types.

Clinical guidelines recently put forth by the American College of Physicians indicate that Pap tests should remain the mainstay of cervical cancer screening in average-risk patients under the age of younger than 30 with HPV testing reserved for older patient populations.

The Centers for Disease Control and Prevention (CDC) discusses the importance of HPV screening, vaccination, and the role of the clinician in helping prevent HPV and related cancers. The video presents three viewpoints: An OB-GYN who treats cervical cancer, a mother / Pediatrician who had her daughters vaccinated for HPV, and a survivor of cervical cancer.

Now that stand-alone HPV tests have been approved, is it worth changing cervical cancer screening recommendations? Juan Felix, MD, weighs in.

Two experts take sides on the clinical merits of performing bilateral salpingectomy alone versus removing the tubes in BRCA mutation carriers.

The GnRH agonist goserelin, when given during chemotherapy, may protect against ovarian failure and early menopause in women with breast cancer.

Hormone replacement therapy won't protect postmenopausal women against stroke or heart disease, but don't discount it for symptoms of menopause just yet.

Clinicians conducting breast examinations who don’t apply enough force during palpation risk missing deeper lesions.

Among BRCA mutation carriers, risk-reducing bilateral salpingo-oophorectomy (RRSO) results in an 80% reduction in risk of ovarian cancer and a 50% reduction in risk of breast cancer if the surgery is performed before the onset of menopause.

Genetic testing for ovarian or endometrial cancer isn't recommended for everyone. Find out here which patients should be referred for testing.

A review of the latest research on the persistence of vasomotor symptoms, the link between hormone therapy and ovarian cancer risk, and the prevalence of substance use in pregnant adolescents.

Ilene Gewirtz, MD, discusses her comprehensive approach to well visits and cancer screens and says education, if not expanded services, is key.

Even brief use of hormone replacement therapy in menopause can increase risk of the 2 most common forms of ovarian cancer, a meta-analysis finds.

Treatments to remove precancerous cervical lesions don't seem to affect a woman's ability to become pregnant, new research found.

Could the approval of bevacizumab for advanced cervical cancer and platinum-resistant ovarian cancer last year lead to patient-specific therapies?

Vaginal estrogens are effective options for managing bothersome symptoms related to genitourinary syndrome of menopause in postmenopausal women.

New evidence reveals that risk prediction for breast cancer is imperative in women with atypical hyperplasia of breast tissue.

According to a new study in Gynecologic Oncology, women who have polycystic ovary syndrome (PCOS) may be at greater risk of developing some types of cancer.

An ADP-ribose polymerase (PARP) inhibitor has received accelerated approval from the US Food and Drug Administration (FDA) for treatment of women with heavily pretreated ovarian cancer associated with defective BRCA genes.